BMO initiates Stryker coverage at Outperform, targets $369
BMO Capital initiated coverage on Stryker with an Outperform rating and a price target of $369. Separately, Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating but lowered the price target to $350 from $355, reflecting a revised valuation assessment.
*this image is generated using AI for illustrative purposes only.
BMO Capital has initiated coverage on Stryker (NYSE: SYK) with an Outperform rating and a price target of $369. This new endorsement comes alongside a revised outlook from Evercore ISI Group, which maintained its Outperform rating but adjusted its valuation expectations downward.
Evercore ISI Group analyst Vijay Kumar affirmed the Outperform rating on Stryker while lowering the price target to $350, down from the previous $355. The reduction reflects a revised assessment of the stock's potential, though the rating affirmation suggests continued confidence in the company's business fundamentals.
The new target from BMO Capital represents a more bullish entry point compared to the adjusted outlook from Evercore. The table below details the current ratings and price targets from both firms.
| Firm | Rating | Price Target |
|---|---|---|
| BMO Capital | Outperform | $369 |
| Evercore ISI | Outperform | $350 |
The consensus among analysts remains focused on Stryker's operational performance and market position. The varying price targets highlight different methodologies in valuing the medical technology company's future earnings and growth trajectory.
What specific factors could drive Stryker's stock price to meet BMO Capital's more bullish target of $369?
How might Stryker's operational performance in the next quarter influence Evercore ISI's revised valuation expectations?
What market trends or competitive dynamics could impact Stryker's growth trajectory and analyst ratings?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
